Executive Summary

• Pre-Seed Funding Secured: GenuForm AI has raised its pre-seed round to establish a certified tissue bank in Budapest and deploy its AI software as an in-house medical device, enabling early clinical traction ahead of MDR certification.
• Clinical Leadership by Prof. Dr. Hangody: co-founder and inventor of Mosaicplasty (OATS) and a global authority in cartilage surgery, anchors the company’s clinical strategy and ensures surgical excellence in AI-guided graft matching.
• Strategic Go-to-Market Path: The company will begin supplying AI-matched grafts in Hungary, Germany, and the UK, generating early revenue while preparing for a transition to a scalable SaaS model for hospitals and tissue banks worldwide.

Budapest, Hungary – September 2025 – GenuForm AI, a pioneering medtech startup transforming knee cartilage transplantation through AI-driven donor-recipient matching, has successfully closed its pre-seed funding round. The investment will enable the company to establish a certified tissue bank in Budapest and deploy its proprietary software as an in-house medical device, laying the groundwork for clinical traction ahead of full MDR certification.

GenuForm AI’s platform leverages deep convolutional neural networks and combinatorial geometry algorithms to match donor and recipient cartilage based on high-resolution MRI-derived 3D geometries. This approach significantly improves surgical outcomes, reduces donor tissue waste, and shortens patient waiting times.

At the heart of GenuForm AI’s innovation is Prof. Dr. László Hangody, internationally renowned orthopedic surgeon and co-founder of the company. Prof. Hangody is the inventor of Mosaicplasty (also known as OATS, or Osteochondral Autograft Transfer System), a groundbreaking technique in cartilage repair, and has led decades of research in osteochondral transplantation. His clinical leadership ensures that GenuForm AI’s technology is deeply rooted in surgical excellence and patient outcomes.

“This funding marks a critical milestone,” said Peter Szoldan, CEO and Founder of GenuForm AI. “It allows us to begin operations as a licensed tissue bank and demonstrate how AI can make biologic knee repair more accessible. By validating our technology in real-world clinical settings, we can generate the clinical evidence needed for MDR and MDSAP approval.”

The company’s immediate focus is to:

• Launch tissue bank operations in Budapest, enabling the harvesting, processing, and distribution of AI-matched cartilage grafts.
• Use its software in-house under the EU MDR Article 5(5) exemption, allowing for clinical use within a healthcare institution while collecting performance and safety data.
• Generate early revenue by supplying grafts to surgeons in Hungary, Germany, and the UK, where demand for biological knee repair is growing rapidly.

GenuForm AI’s long-term vision is to transition to a high-growth SaaS model, licensing its AI platform to hospitals and tissue banks globally. The company is supported by a world-class team of orthopedic surgeons, radiologists, AI researchers, and regulatory experts.

With this pre-seed round, GenuForm AI is set to redefine cartilage transplantation—offering patients a more precise, biologically compatible alternative to artificial knee replacements.